0000921895-21-002138.txt : 20210817 0000921895-21-002138.hdr.sgml : 20210817 20210817180715 ACCESSION NUMBER: 0000921895-21-002138 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210813 FILED AS OF DATE: 20210817 DATE AS OF CHANGE: 20210817 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Myrexis, Inc. CENTRAL INDEX KEY: 0001459450 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-12957 FILM NUMBER: 211184403 BUSINESS ADDRESS: STREET 1: 600 FIFTH AVENUE, 2ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10020 BUSINESS PHONE: 801-214-7800 MAIL ADDRESS: STREET 1: 600 FIFTH AVENUE, 2ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10020 FORMER NAME: FORMER CONFORMED NAME: Myriad Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20090324 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: COUCHMAN JONATHAN CENTRAL INDEX KEY: 0001265094 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-12957 FILM NUMBER: 211184406 MAIL ADDRESS: STREET 1: 630 FIFTH AVENUE STREET 2: SUITE 2260 CITY: NEW YORK STATE: NY ZIP: 10020 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Couchman Family Fund CENTRAL INDEX KEY: 0001737322 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-12957 FILM NUMBER: 211184405 BUSINESS ADDRESS: STREET 1: 630 FIFTH AVENUE, SUITE 2260 CITY: NEW YORK STATE: NY ZIP: 10020 BUSINESS PHONE: (212) 729-4962 MAIL ADDRESS: STREET 1: 630 FIFTH AVENUE, SUITE 2260 CITY: NEW YORK STATE: NY ZIP: 10020 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Xstelos Corp. CENTRAL INDEX KEY: 0001571659 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-12957 FILM NUMBER: 211184404 BUSINESS ADDRESS: STREET 1: 630 FIFTH AVENUE STREET 2: SUITE 2260 CITY: NEW YORK STATE: NY ZIP: 10020 BUSINESS PHONE: 212.729.4962 MAIL ADDRESS: STREET 1: 630 FIFTH AVENUE STREET 2: SUITE 2260 CITY: NEW YORK STATE: NY ZIP: 10020 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ENZON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000727510 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 222372868 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 20 COMMERCE DRIVE, SUITE 135 CITY: CRANFORD STATE: NJ ZIP: 07016 BUSINESS PHONE: 732-980-4500 MAIL ADDRESS: STREET 1: 20 COMMERCE DRIVE, SUITE 135 CITY: CRANFORD STATE: NJ ZIP: 07016 FORMER COMPANY: FORMER CONFORMED NAME: ENZON PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060324 FORMER COMPANY: FORMER CONFORMED NAME: ENZON PHARMACEUTICALS INC DATE OF NAME CHANGE: 20021211 FORMER COMPANY: FORMER CONFORMED NAME: ENZON PHARMACEUTICAL INC DATE OF NAME CHANGE: 20021210 4 1 form405735004_08172021.xml OWNERSHIP DOCUMENT X0306 4 2021-08-13 0 0000727510 ENZON PHARMACEUTICALS, INC. ENZN 0001265094 COUCHMAN JONATHAN 600 FIFTH AVENUE 2ND FLOOR NEW YORK NY 10020 0 0 1 0 0001737322 Couchman Family Fund 600 FIFTH AVENUE 2ND FLOOR NEW YORK NY 10020 0 0 1 0 0001571659 Xstelos Corp. 600 FIFTH AVENUE 2ND FLOOR NEW YORK NY 10020 0 0 1 0 0001459450 Myrexis, Inc. 600 FIFTH AVENUE 2ND FLOOR NEW YORK NY 10020 0 0 1 0 Common Stock, $0.01 par value 4717666 I By Jonathan Couchman Common Stock, $0.01 par value 2021-08-13 4 S 0 50000 0.3898 D 350000 I By Couchman Family Fund Common Stock, $0.01 par value 2021-08-13 4 S 0 57500 0.3898 D 2043024 I By Xstelos Corp. Common Stock, $0.01 par value 633264 I By Myrexis, Inc. This Form 4 is filed jointly by Jonathan Couchman ("Mr. Couchman"), Couchman Family Fund (the "Foundation"), Xstelos Corp. ("Xstelos") and Myrexis, Inc. ("Myrexis") (collectively, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock (the "Shares"). Each of the Reporting Persons expressly disclaims beneficial ownership of the Shares reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such Shares for purposes of Section 16 or for any other purpose. Represents shares owned directly by Mr. Couchman. As the sole trustee of the Foundation, Mr. Couchman may be deemed to beneficially own the Shares owned by the Foundation. As the Chief Executive Officer of Xstelos, Mr. Couchman may be deemed to beneficially own the shares of Common Stock owned by Xstelos. As the Chief Executive Officer of Myrexis, Mr. Couchman may be deemed to beneficially own Shares of Common Stock owned by Myrexis. Represents Shares owned directly by the Foundation. Mr. Couchman is the sole trustee of the Foundation. By virtue of this relationship, Mr. Couchman may be deemed to beneficially own the Shares owned directly by the Foundation, however he has no pecuniary interest in such Shares. Represents Shares owned directly by Xstelos. Mr. Couchman is the controlling shareholder and Chief Executive Officer of Xstelos. By virtue of these relationships, Mr. Couchman may be deemed to beneficially own the Shares owned directly by Xstelos. Mr. Couchman expressly disclaims beneficial ownership of such Shares except to the extent of his pecuniary interest therein. Represents Shares owned directly by Myrexis. Mr. Couchman is Chief Executive Officer of Myrexis. By virtue of this relationship, Mr. Couchman may be deemed to beneficially own the Shares owned directly by Myrexis. Mr. Couchman expressly disclaims beneficial ownership of such Shares except to the extent of his pecuniary interest therein. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions and the reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commision, upon request, full information regarding the number of shares purchased at each separate price. Effective September 17, 2020, Michael Pearce, Brian Harper and Harper Asset Management, LLC ceased to be members of the Section 13(d) group and ceased to be Reporting Persons. /s/ Jonathan Couchman 2021-08-17 Couchman Family Fund; By: /s/ Jonathan Couchman, Trustee 2021-08-17 Xstelos Corp.; By: /s/ Jonathan Couchman, Chief Executive Officer 2021-08-17 Myrexis, Inc.; By: /s/ Jonathan Couchman, Chief Executive Officer 2021-08-17